Pfizer (PFE) EV to EBITDA (2009 - 2026)

Pfizer (PFE) has reported EV to EBITDA for 18 consecutive years, with 29.79 the latest figure, recorded in Q2 2026.

• On a quarterly basis, EV to EBITDA rose 20.78% year-over-year to 29.79 in Q2 2026; TTM through Jun 2026 was 6.23, a 31.68% increase from a year earlier, with the FY2025 full-year figure at 6.19, down 15.35% from the prior year.
• EV to EBITDA was 29.79 for Q2 2026 at Pfizer, up from 26.41 in the prior quarter.
• Over five years, EV to EBITDA peaked at 65.51 in Q2 2024 and troughed at 10.66 in Q4 2023.
• A 5-year average of 26.25 and a median of 25.94 in 2025 frame the typical range for EV to EBITDA.
• Across the five-year window, EV to EBITDA surged 138.6% in 2023 and plunged 62.35% in 2025, its largest moves.
• Over 5 years, EV to EBITDA stood at 19.98 in 2022, then tumbled by 153.36% to 10.66 in 2023, then soared by 203.9% to 11.08 in 2024, then surged by 168.62% to 29.75 in 2025, then climbed by 0.12% to 29.79 in 2026.
• The last three EV to EBITDA figures came in at 29.79 (Q2 2026), 26.41 (Q1 2026), and 29.75 (Q4 2025), per Business Quant data.